Payers' views of the changes arising through the possible adoption of adaptive pathways

Frontiers in Pharmacology

Volumn 7, Issue SEP, 2016, Pages

  Ermisch, Michael ^a   Bucsics, Anna ^b   Bonanno, Patricia Vella ^c   Arickx, Francis ^d   Bybau, Alexander ^e   Bochenek, Tomasz ^f   van de Casteele, Marc ^d   Diogene, Eduardo ^g   Fürst, Jurij ^h   Garuoliene, Kristina ^i,j   van der Graaff, Martin ^k   Gulbinovic, Jolanta ^i,l   Haycox, Alan ^m   Jones, Jan ⁿ   Joppi, Roberta ^o   Laius, Ott ^p   Langner, Irene ^q   Martin, Antony P ^m   Markovic Pekovic, Vanda ^r,s   McCullagh, Laura ^t   Magnusson, Einar ^u   Nilsen, Ellen ^v   Selke, Gisbert ^q   Sermet, Catherine ^w   Simoens, Steven ^x   Sauermann, Robert ^y   Schuurman, Ad ^k   Ramos, Ricardo ^z   Vlahovic Palcevski, Vera ^aa   Zara, Corinne ^ab   Godman, Brian ^m,ac,ad   more..

^a National Association of Statutory Health Insurance Funds   (Germany)

^b UNIVERSITY OF VIENNA   (Austria)

^c Independent Pharmaceutical Consultant   (Malta)

^d National Institute for Health and Disability Insurance   (Belgium)

^e Zilveren Kruis Achmea ^*  (Netherlands)

^f JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^g HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^h Health Insurance Institute of Slovenia   (Slovenia)

ⁱ VILNIUS UNIVERSITY   (Lithuania)

^j National Health Insurance Fund   (Lithuania)

^k National Health Care Institute   (Netherlands)

^l State Medicine Control Agency of Lithuania   (Lithuania)

^m UNIVERSITY OF LIVERPOOL MANAGEMENT SCHOOL   (United Kingdom)

ⁿ Scottish Medicines Consortium   (United Kingdom)

^o Pharmaceutical Drug Department   (Italy)

^p State Agency of Medicines   (Estonia)

^q Wissenschaftliches Institut der AOK WIdO   (Germany)

^r MINISTRY OF HEALTH AND SOCIAL WELFARE   (Bosnia and Herzegovina)

^s UNIVERSITY OF BANJA LUKA   (Bosnia and Herzegovina)

^t TRINITY COLLEGE DUBLIN   (Ireland)

^u Ministry of Health   (Iceland)

^v Norweigian Directorate for Health   (Norway)

^w Institut de recherche et documentation en économie de la santé   (France)

^x UNIVERSITY OF LEUVEN   (Belgium)

^y Main Assoc Austrian Social Ins I   (Austria)

^z INFARMED)   (Portugal)

^aa KBC RIJEKA   (Croatia)

^ab C Agy Hlth Technol Assess Res   (Spain)

^ac UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^ad KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

Adaptive pathways; EMA; Europe; Marketing authorization; Payers

Indexed keywords

NEW DRUG;

ARTICLE; COMORBIDITY; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG EXPOSURE; DRUG INDICATION; DRUG MARKETING; DRUG SAFETY; DRUG USE; FUNDING; HUMAN; LICENSING; LIFE THREAT; PATIENT; PHASE 3 CLINICAL TRIAL (TOPIC); PRESCRIPTION; RESPONSIBILITY; RISK FACTOR; UNCERTAINTY;

EID: 84991786795     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2016.00305     Document Type: Article

References (62)

1. Adamski, J., Godman, B., Ofierska-Sujkowska, G., Osinska, B., Herholz, H., Wendykowska, K., et al. (2010). Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. BMC Health Services Res. 10:153. doi: 10.1186/1472-6963-10-153
2. Annemans, L., Cleemput, I., Hulstaert, F., and Simoens, S. (2012). Comparative effectiveness research and measuring the level of pharmaceutical innovation in the EU. J. Comp. Effectiv. Res. 1, 19-29. doi: 10.2217/cer.11.1
3. Arrowsmith, J. (2011). Trial watch: phase III and submission failures: 2007-2010. Nat. Rev. Drug Disc. 10:87. doi: 10.1038/nrd3375
4. Baird, L. G., Banken, R., Eichler, H. G., Kristensen, F. B., Lee, D. K., Lim, J. C., et al. (2014). Accelerated access to innovative medicines for patients in need. Clin. Pharmacol. Therap. 96, 559-571. doi: 10.1038/clpt.2014.145
5. Banzi, R., Gerardi, C., Bertele, V., and Garattini, S. (2015). Approvals of drugs with uncertain benefit-risk profiles in Europe. Eur. J. Inter. Med. 26, 572-584. doi: 10.1016/j.ejim.2015.08.008
6. Brennan, T., and Shrank, W. (2014). New expensive treatments for hepatitis C infection. JAMA 312, 593-594. doi: 10.1001/jama.2014.8897
7. Campbell, S. M., Godman, B., Diogene, E., Furst, J., Gustafsson, L. L., MacBride-Stewart, S., et al. (2015). Quality indicators as a tool in improving the introduction of new medicines. Basic Clin. Pharmacol. Toxicol. 116, 146-157. doi: 10.1111/bcpt.12295
8. Cerreta, F. (2015). EMA Adaptive Pathways Pilot Presentation at STAMP. Available at URL: http://www.ema.europa.eu/docs/en_GB/document_library/Presentation/2015/11/WC500196727.pdf
9. Cohen, D. (2014). Dabigatran: how the drug company withheld important analyses. BMJ 349:g4670. doi: 10.1136/bmj.g4670
10. Cohen, P., and Felix, A. (2014). Are payers treating orphan drugs differently? J. Market Access Health Pol. 2:23513. doi: 10.3402/jmahp.v2.23513
11. Cortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J. P., Wolmark, N., et al. (2014). Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384, 164-172. doi: 10.1016/S0140-6736(13)62422-8
12. Davis, C., Lexchin, J., Jefferson, T., Gotzsche, P., and McKee, M. (2016). "Adaptive pathways" to drug authorisation: adapting to industry? BMJ open. BMJ 354:i4437. doi: 10.1136/bmj.i4437
13. de Bruijn, W., Ibanez, C., Frisk, P., Bak Pedersen, H., Alkan, A., Vella Bonanno, P., et al. (2016). Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future. Front. Pharmacol. 7:197. doi: 10.3389/fphar.2016.00197
14. Eichler, H. G., Abadie, E., Breckenridge, A., Flamion, B., Gustafsson, L. L., Leufkens, H., et al. (2011). Bridging the efficacy-effectiveness gap: a regulator's perspective on addressing variability of drug response. Nat. Rev. Drug Disc. 10, 495-506. doi: 10.1038/nrd3501
15. Eichler, H. G., Baird, L., Barker, R., Bloechl-Daum, B., Borlum-Kristensen, F., Brown, J., et al. (2015). From adaptive licensing to adaptive pathways: delivering a flexible life-span approach to bring new drugs to patients. Clin. Pharmacol. Ther. 97, 234-246. doi: 10.1002/cpt.59
16. Eichler, H. G., Hurts, H., Broich, K., and Rasi, G. (2016). Drug regulation and pricing-can regulators influence affordability? New Engl. J. Med. 374, 1807-1809. doi: 10.1056/NEJMp1601294
17. Eichler, H. G., Oye, K., Baird, L. G., Abadie, E., Brown, J., Drum, C. L., et al. (2012). Adaptive licensing: taking the next step in the evolution of drug approval. Clin. Pharmacol. Ther. 91, 426-437. doi: 10.1038/clpt.2011.345
18. Experts in Chronic Myeloid Leukemia (2013). The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 121, 4439-4442. doi: 10.1182/blood-2013-03-490003
19. Ferrario, A., and Kanavos, P. (2013). Managed Entry Agreements for Pharmaceuticals: The European Experience: LSE. Available at URL: http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/mea_report_en.pdf
20. Ferrario, A., and Kanavos, P. (2015). Dealing with uncertainty and high prices of new medicines: a comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden. Soc. Sci. Med. 124, 39-47. doi: 10.1016/j.socscimed.2014.11.003
21. Frank, C., Himmelstein, D. U., Woolhandler, S., Bor, D. H., Wolfe, S. M., Heymann, O., et al. (2014). Era of faster FDA drug approval has also seen increased black-box warnings and market withdrawals. Health Affairs 33, 1453-1459. doi: 10.1377/hlthaff.2014.0122
22. Garattini, S. (2012). Time to revisit the orphan drug law. Eur. J. Clin. Pharmacol. 68, 113. doi: 10.1007/s00228-011-1115-3
23. Godman, B., Finlayson, A. E., Cheema, P. K., Zebedin-Brandl, E., Gutierrez-Ibarluzea, I., Jones, J., et al. (2013). Personalizing health care: feasibility and future implications. BMC Med. 11:179. doi: 10.1186/1741-7015-11-179
24. Godman, B., Joppi, R., Bennie, M., Jan, S., and Wettermark, B. (2016). "Managed introduction of new drugs," in Drug Utilization Research: Methods and Applications, eds M. Wettermark et al. (Chichester: John Wiley and Sons), 210-221.
25. Godman, B., Malmstrom, R. E., Diogene, E., Gray, A., Jayathissa, S., Timoney, A., et al. (2015). Are new models needed to optimize the utilization of new medicines to sustain healthcare systems? Exp. Rev. Clin. Pharmacol. 8, 77-94. doi: 10.1586/17512433.2015.990380
26. Godman, B., Malmstrom, R. E., Diogene, E., Jayathissa, S., McTaggart, S., Cars, T., et al. (2014). Dabigatran-a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs. Front. Pharmacol. 5:109. doi: 10.3389/fphar.2014.00109
27. Godman, B., Malmstrom, R., Bennie, M., Sakshaug, S., Burkhardt, T., Campbell, S., Garuoliene, K., Lonsdale, J., et al. (2012a). Prescribing restrictions-a necessary strategy among some European countries to enhance future prescribing efficiency?'. Rev. Health Care. 3, 5-16. doi: 10.7175/rhc.v3i1.55
28. Godman, B., Paterson, K., Malmstrom, R. E., Selke, G., Fagot, J. P., and Mrak, J. (2012b). Improving the managed entry of new medicines: sharing experiences across Europe. Exp. Rev. Pharmacoeconom. Outcomes Res. 12, 439-441. doi: 10.1586/erp.12.44
29. Godman, B., Shrank, W., Andersen, M., Berg, C., Bishop, I., Burkhardt, T., et al. (2010). Policies to enhance prescribing efficiency in europe: findings and future implications. Front. Pharmacol. 1:141. doi: 10.3389/fphar.2010.00141
30. Hawkes, N. (2016a). Specialists attack drug agency's fast track approval scheme. BMJ 353:i3060. doi: 10.1136/bmj.i3060
31. Hawkes, N. (2016b). German body calls for pause in European plan for fast track drug approval. BMJ 354:i4479. doi: 10.1136/bmj.i4479
32. Henshall, C. S. L., Eichler, H.-G., Lemgruber, A., Longson, C., O'Rourke, B., and Tunis, S. (2014). Understanding the role and evidence expectations of health technology assessment and coverage/payer bodies: what are they looking for, and how and why does this differ from what regulators require? Ther. Inn. Regul. Sci. 48, 341-346. doi: 10.1177/2168479013512488
33. Howard, D. H., Bach, P., Berndt, E. R., and Conti, R. M. (2015). Pricing in the market for anticancer drugs. J. Econ. Persp. 29, 139-162. doi: 10.1257/jep.29.1.139
34. Husereau, D., Henshall, C., and Jivraj, J. (2014). Adaptive approaches to licensing, health technology assessment, and introduction of drugs and devices. Int. J. Technol. Assess. Health Care 30, 241-249. doi: 10.1017/S0266462314000191
35. Hyman, D. M., Puzanov, I., Subbiah, V., Faris, J. E., Chau, I., Blay, J. Y., et al. (2015). Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. NEJM 373, 726-736. doi: 10.1056/NEJMoa1502309
36. International Society of Drug Bulletins (2016). EMA's Report on Adaptive Pathways: Little Data and Much Ado About Nothing. Brussels: International Society of Drug Bulletins, Medicines in Europe Forum, Nordic Cochrane Centre. 31 August Press Release. Available online at: http://english.prescrire.org/en/79/207/46302/4983/4785/SubReportDetails.aspx
37. Joppi, R., Cinconze, E., Mezzalira, L., Pase, D., Poggiani, C., Rossi, E., et al. (2013). Hospitalized patients with atrial fibrillation compared to those included in recent trials on novel oral anticoagulants: a population-based study. Eur. J. Int. Med. 24, 318-323. doi: 10.1016/j.ejim.2013.02.018
38. Joppi, R., Dematte, L., Menti, A. M., Pase, D., Poggiani, C., and Mezzalira, L. (2009). The Italian Horizon Scanning Project. Eur. J. Clin. Pharmacol. 65, 775-781. doi: 10.1007/s00228-009-0666-z
39. Joppi, R., Gerardi, C., Bertele', V., and Garattini, S. (2016). Letting post-marketing bridge the evidence gap: the case of orphan drugs. BMJ 353:i2978. doi: 10.1136/bmj.i2978
40. Kantarjian, H. M., Fojo, T., Mathisen, M., and Zwelling, L. A. (2013). Cancer drugs in the United States: Justum Pretium-the just price. J. Clin. Oncol. 31, 3600-3604. doi: 10.1200/JCO.2013.49.1845
41. Kaplan, W., Wirtz, V., Mantel-Teeuwisse, A., Stolk, P., Duthey, B., and Laing, R. (2013). Priority Medicines for Europe and the World 2013 Update Report. Available at URL: http://www.who.int/medicines/areas/priority_medicines/MasterDocJune28_FINAL_Web.pdf?ua=1
42. Kelly, R. J., and Smith, T. J. (2014). Delivering maximum clinical benefit at an affordable price: engaging stakeholders in cancer care. Lancet Oncol. 15, e112-e118. doi: 10.1016/S1470-2045(13)70578-3
43. Kesselheim, A. S., Myers, J. A., Solomon, D. H., Winkelmayer, W. C., Levin, R., and Avorn, J. (2012). The prevalence and cost of unapproved uses of top-selling orphan drugs. PLoS ONE 7:e31894. doi: 10.1371/journal.pone.0031894
44. Leopold, C., Vogler, S., Mantel-Teeuwisse, A. K., de Joncheere, K., Leufkens, H. G., and Laing, R. (2012). Differences in external price referencing in Europe: a descriptive overview. Health Policy 104, 50-60. doi: 10.1016/j.healthpol.2011.09.008
45. Malmstrom, R. E., Godman, B. B., Diogene, E., Baumgartel, C., Bennie, M., Bishop, I., et al. (2013). Dabigatran-a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. Front. Pharmacol. 4:39. doi: 10.3389/fphar.2013.00039
46. Mangiapane, S., and Velasco Garrido, M. (2009). Use of Surrogate end points in HTA. GMS Health Technol. Assess. 5:Doc12. doi: 10.3205/hta000074
47. Marra, L. P., Araujo, V. E., Silva, T. B., Diniz, L. M., Guerra Junior, A. A., Acurcio, F. A., et al. (2016). Clinical effectiveness and safety of analog glargine in type 1 diabetes: a systematic review and meta-analysis. Diabetes Ther. 7, 241-258. doi: 10.1007/s13300-016-0166-y
48. Matusewicz, W., Godman, B., Pedersen, H. B., Furst, J., Gulbinovic, J., Mack, A., et al. (2015). Improving the managed introduction of new medicines: sharing experiences to aid authorities across Europe. Exp. Rev. Pharmacoeconom. Outcomes Res. 15, 755-758. doi: 10.1586/14737167.2015.1085803
49. Naci, H., Lehman, R., Wouters, O. J., Goldacre, B., and Yudkin, J. S. (2015). Rethinking the appraisal and approval of drugs for type 2 diabetes. BMJ 351:h5260. doi: 10.1136/bmj.h5260
50. Paris, V., and Belloni, A. (2013). Value in Pharmaceutical Pricing. OECD Health Working Papers, No. 63: OECD Publishing. doi: 10.1787/5k43jc9v6knx-en
51. Permanand, G., and Bak Pedersen, H. (2015). Managing new premium-priced medicines in Europe. J. Pharmaceut. Policy Pract. 8(Suppl. 1), 1-3. doi: 10.1186/2052-3211-8-s1-k2
52. Phelan, M., and Cook, C. (2014). A treatment revolution for those who can afford it? Hepatitis C treatment: new medications, profits and patients. BMC Infect. Dis. 14 (Suppl. 6):S5. doi: 10.1186/1471-2334-14-S6-S5
53. Picavet, E., Cassiman, D., Hollak, C. E., Maertens, J. A., and Simoens, S. (2013). Clinical evidence for orphan medicinal products-a cause for concern? Orphanet J. Rare Dis. 8, 164. doi: 10.1186/1750-1172-8-164
54. Prasad, V., Kim, C., Burotto, M., and Vandross, A. (2015). The strength of association between surrogate end points and survival in oncology: a systematic review of trial-level meta-analyses. JAMA Int. Med. 175, 1389-1398. doi: 10.1001/jamainternmed.2015.2829
55. Prescrire Editorial (2016). New drugs, new indications in 2015: little progress, and threats to access to quality healthcare for all. Rev. Prescrire 36, 133-137.
56. Raftery, J. (2010). Multiple sclerosis risk sharing scheme: a costly failure. BMJ 340:c1672. doi: 10.1136/bmj.c1672
57. Redig, A. J., and Janne, P. A. (2015). Basket trials and the evolution of clinical trial design in an era of genomic medicine. J. Clin. Oncol. 33, 975-977. doi: 10.1200/JCO.2014.59.8433
58. Simoens, S., Picavet, E., Dooms, M., Cassiman, D., and Morel, T. (2013). Cost-effectiveness assessment of orphan drugs: a scientific and political conundrum. Appl. Health Econ. Health Policy 11, 1-3. doi: 10.1007/s40258-012-0004-y
59. Svensson, S., Menkes, D. B., and Lexchin, J. (2013). Surrogate outcomes in clinical trials: a cautionary tale. JAMA Int. Med. 173, 611-612. doi: 10.1001/jamainternmed.2013.3037
60. Tuma, R. (2009). Progression-free survival remains debatable endpoint in cancer trials. J. Natl. Cancer Ins. 101, 1439-1441. doi: 10.1093/jnci/djp399
61. Velasco Garrido, M., and Mangiapane, S. (2009). Surrogate outcomes in health technology assessment: an international comparison. Int. J. Technol. Asses. Health Care 25, 315-322. doi: 10.1017/S0266462309990213
62. Wettermark, B., Persson, M. E., Wilking, N., Kalin, M., Korkmaz, S., Hjemdahl, P., et al. (2010). Forecasting drug utilization and expenditure in a metropolitan health region. BMC Health Services Res. 10:128. doi: 10.1186/1472-6963-10-128